Nodular lymphocyte predominant Hodgkin's lymphoma.
OBJECTIVE
To describe the clinicopathological features, treatment, treatment outcome and sequelae of patients with nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) in a Saudi population.


METHODS
This is a retrospective review of 29 patients with lymphocyte predominant Hodgkin's lymphoma treated at 2 major hospitals (King Khalid University Hospital and Security Forces Hospital) in Riyadh, Kingdom of Saudi Arabia from 1985 to 2000. Histological subtypes were confirmed by review of hematoxylin and eosin paraffin sections and immunochemistry. Details of clinical presentation, stage, treatment and results of treatment were analyzed.


RESULTS
On pathological reappraisal of the 29 cases, 3 patients had nodular sclerosis Hodgkin's lymphoma and 4 patients were reclassified as lymphocyte rich classical Hodgkin's lymphoma. Twenty-two patients were identified to have nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL). These patients comprised of 18 male and 4 female patients with a median age at presentation of 25 years. Nineteen (86%) patients had an early stage (Ann Arbor stage I and II) disease, 2 had stage III and one patient had a stage IV. The majority of the patients presented with peripheral lymphadenopathy and long duration of symptoms. For 16 patients, details of treatment and follow-up were available. All of these achieved a complete response to initial treatment. Four patients relapsed following the primary therapy.


CONCLUSIONS
Our results are consistent with the previous series reported from Western countries and confirm that patients with NLPHL have a characteristic clinical and pathological profile that distinguish it from other types of Hodgkin's lymphoma. The disease tends to run an unusual course and although most patients achieve an excellent response to therapy there is a tendency to relapse. Treatment remains controversial; however, recent understanding of the molecular pathogenesis of NLPHL could lead to modification of current therapeutic approach to this disease.
Siddiqui
Neelam
N
Division of Oncology, Department of Medicine (38), College of Medicine, King Khalid University Hospital, PO Box 2925, Riyadh 11461, Kingdom of Saudi Arabia. neelamsiddiqui@hotmail.com
Al-Diab
Abdulrahman I
AI
D000293:Adolescent; D000328:Adult; D005260:Female; D006689:Hodgkin Disease / Q000473:pathology* / Q000628:therapy; D006801:Humans; D016130:Immunophenotyping; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies